Neuroendocrine stains and proliferative indices of prostatic adenocarcinomas in transurethral resection samples

British Journal of Urology

Volumn 80, Issue 2, 1997, Pages 281-286

  Speights, V O ^a,b,c,d   Cohen, M K ^a   Riggs, M W ^a   Coffield, K S ^a   Keegan, G ^a   Arber, D A ^a  

^a Department of Pathology ^*  (United States)

^b SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^c TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^d UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

Neuroendocrine markers; Proliferative index; Prostate cancer; Transurethral resection

Indexed keywords

CHROMOGRANIN A; MARKER; NEURON SPECIFIC ENOLASE; PROSTATE SPECIFIC ANTIGEN; SYNAPTOPHYSIN;

ADULT; AGED; ARTICLE; BIOPSY; CANCER STAGING; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; MALE; NEUROSECRETORY CELL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; STAIN; TRANSURETHRAL RESECTION; TUMOR GROWTH;

AGED; AGED, 80 AND OVER; CELL DIVISION; CHROMOGRANIN A; CHROMOGRANINS; COLORING AGENTS; HUMANS; MALE; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; PHOSPHOPYRUVATE HYDRATASE; PROSTATIC NEOPLASMS; SYNAPTOPHYSIN;

EID: 0031403615     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Cohen RJ, Glezerson G, Taylor LF, HA, Naude JH. The neuroendocrine cell population of the human prostate gland. J Ural 1993; 150: 365-8
2. Speights VO, Cohen MK, Coffleld KS, Keegan GT, McClintock J, Arber DA. Neuroendocrine staining of malignant, hyperplastic, and atrophie prostate tissue. Appl Immunohistochem 1994; 2: 212-17
3. Abrahamsson PA. Falkner S, Fait K, Grimelius L. The course of neuroendocrine differentiation in prostatic carcinomas: an immunohistochemical study testing chromogranin A as an 'endocrine marker'. Pathol Res Pract 1989; 185: 373-80
4. Berner A, Nesland JM, Waehre H, Silde J. Fossâ SD. Hormone résistant prostatic adenocarcinoma. An évaluation of prognostic factors in pre- and post-treatment specimens. Br J Cancer 1993; 68: 380-4
5. Bostwick DG, Dousa MK, Crawford BG. Wollan PC. Neuroendocrine differentiation in prostatic intraepithelial neoplasia and adenocarcinoma. Am J Surg Pathol 1994; 18: 1240-6
6. diSant'Agnese PA. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic and therapeutic implications. Cancer 1992; 70: 254-68
7. Cohen RJ. Glezerson G, Haffejee Z, Afrika D. Prostatic carcinoma: histologie and immunohistochemical factors affecting prognosis. Br J Urol 1990; 66: 405-10
8. Cohen RJ, Glezerson G. Haffejee Z. Neuro-endocrine cells a new prognostic parameter in prostate cancer. Br J Urol 1991; 68: 259-62
9. diSant'Agnese PA, Cockett AT. The prostatic endocrineparacrine (neuroendocrine) regulatory system and neuroendocrine differentiation in prostatic carcinoma: a review and future directions in basic research. J Urol 1994; 152: 1927-31
10. Aprikian AG, Cordon-Cardo C, Fair WR et al. Neuroendocrine differentiation in metastadc prostatic adenocarcinoma. J Urol 1994; 151: 914-9
11. Cohen MK, Arber DA, Coffleld KS, Keegan GT, McClintock J, Speights VO Neuroendocrine differentiation and prostatic adenocarcinoma and its relationship to tumor progression. Cancer 1994; 74: 1899-1903
12. Berner A, Waere H, Nesland JM, Paus E, Danielsen HE, Fossa SD. DNA ploidy, sérum prostate specific antigen, histological grade and immunohistochemistry as prédictive parameters of lymph node métastases in Tl-T3/Mo prostatic adenocarcinoma. Br J Urol 1995; 75: 26-32
13. Botticelli AR, Crisuolo M, Martinelli AM, Botticelli L, Filoni A, Migaldi M. Proliferating cell nuclear antigen/cyclin in incidental carcinoma of the prostate. Virch Arch 1993: 423: 365-8
14. Carrol ER, Waldman FM, Rosenau W et al Cell proliferation and prostatic adenocarcinoma: in-vitro measurement by 5-bromodeoxyuridine incorporation in proliferating cell nuclear antigen. J Urol 1993; 149: 403-7
15. Harper ME, Glynne-Jones E, Goddard L et al. Relationship of proliferating cell nuclear antigen (PCNA) in prostatic carcinoma to various clinical parameters. Prostate 1992; 27: 243-53
16. Spires SE, Banks ER, Davey DD, Jennings CD, Wood DP Jr, Cibull ML. Proliferating cell nuclear antigen in prostatic adenocarcinoma: correlation with established prognostic factors. Urology 1994; 43: 660-6
17. Sakr A, Sarkar FH. Sreephtahi P, Drozdowicz S, Chrissman JD. Measurement of cellular proliferation in human prostate by AgNOR, PCNA, and SPF. Prostate 1993; 22: 147-54
18. Visakorpi T, Kallioniemi OP, Heikkinen A, Koivula T, Isola J. Small subgroup of aggressive highly proliferative prostatic carcinomas defined by P53 accumulation. J Nad Cancer Inst 1992; 84: 883-7
19. Deitch AD, deVere White RW. Flow cytometry as a predictive modality in prostate cancer. Hum Pathol 1992; 23: 352-9
20. Dervan PA, Gilmartin L.G., Loftus BM, Carney DN. Breast carcinoma kinetics. Argyrophilic nucleolar organizer region counts correlate with Ki67 scores. Am J Clin Pathol 1989; 92: 401-7
21. Vielh P, Chevillard S, Mosseri V, Bonatini B, Magdelengt H. Ki67 index and S-phase fraction in breast carcinomas: comparison and correlations with prognostic factors. Am J Clin Pathol 1990; 94: 681-6
22. Grogan TM, Lippman SM, Spier CM et al. Independent diagnostic significance of a nuclear proliferating antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki67. Blood 1988; 71: 1157-60
23. Key G, Becker MHG, Duchrow M, Schulter C, Gerdes J. New Ki67 equivalent murine monoclonal antibodies (MIB1-3) prepared against recombinant parts of the Ki67 antigen. Anal Cell Pathol 1992: 4: 181(Abstract 186)
24. Krishna M, Kahn A, Woda B, Menon M, Malhotra R. Expression and prognostic significance of p53, Ki67 and c-erbB-2 in prostate carcinomas. Mod Pathol 1995; 8: 79A
25. Limus C, Vrizelle SP, Holt TJ. Proliferative activity of benign neoplastic prostate epithelium. Mod Pathol 1994; 7: 79A
26. American Joint Committee on Cancer. Manual for Staging of Cancer. 4th edn. Philadelphia: JB Lippincott Company, 1992: 181-6
27. Cohen MK, Riggs MW, Brawn PN, Spiekerman AM, Speights VO. Serum prostate specific antigen levels in stage A-l prostate cancer. Am J Clin Pathol 1993; 100: 127-9
28. Sheibani K, Tubbs RR. Enzyme immunohistochemistry: technical aspects. Semin Diagn Pathol 1984; 1: 235-50
29. Gown AM, deWever N, Battifora H. Microwave based antigenic unmasking. A revolutionary new technique for routine immunohistochemistry. Appl Immunohistochem 1993; 1: 256-6
30. Aprikian AG, Cordon-Cardo C. Fair WR, Reuter VE. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer 1993; 71: 3952-65
31. Krijen JL, Janssen PJ, Ruizveld de Winter JA. van Krimpen H, Schroeder FH, van der Kwast TH. The neuroendocrine cells in human prostate cancer express antigen receptor. Histochemistry 1993; 100: 393-8